GlaxoSmithKline News

Unusual Options Activity: MS, PFE and Others Attract Market Bets, MS V/OI Ratio Reaches 131.9

EST Apr 29th Afternoon Delivery - In the last two hours of trading, 6 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends

moomoo News1minutes ago

20 Fastest Growing Health Tech Companies in the World

Yahoo FinanceApr 25 11:34 ET

Express News | Glaxosmithkline Sues Pfizer and BioNTech Over Mrna Technology Patents in Covid-19 Vaccines - US Court Filing

ReutersApr 25 09:18 ET

CureVac Begins Early Stage Portion of Investigational Vaccine Trial

CureVac (CVAC) said Wednesday it initiated the early stage portion of a broader study into an investigational flu vaccine developed with GSK (GSK). The phase 1 trial is part of a combined phase 1/2 st

MT NewswiresApr 24 12:27 ET

Express News | CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus

Moomoo 24/7Apr 24 07:20 ET

Express News | CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health

Moomoo 24/7Apr 24 07:18 ET

Express News | The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer

Moomoo 24/7Apr 24 06:58 ET

Sanofi Reportedly Lining up Banks for Consumer Products Spinoff

Seeking AlphaApr 23 13:32 ET

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA

BenzingaApr 23 10:22 ET

Express News | NYSE Order Imbalance 172887.0 Shares on Sell Side

Moomoo 24/7Apr 22 15:50 ET

Unusual Options Activity: CSX, FNV and Others Attract Market Bets, CSX V/OI Ratio Reaches 152.2

EST Apr 22nd Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend

moomoo NewsApr 22 13:30 ET

Express News | Sanofi To Pay $100M To Settle Zantac Cancer Lawsuits

Moomoo 24/7Apr 22 10:31 ET

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 19 17:10 ET

Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges

Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significant factor exacerbating the country's struggle to mana

BenzingaApr 19 11:39 ET

The protective effect reached 82% after 10 years! Long-term follow-up results of GSK (GSK.US) shingles vaccine announced

The Zhitong Finance App learned that GSK (GSK.US) recently announced its recombinant herpes zoster vaccine Shingrix (RZV), which obtained positive data in the long-term follow-up phase 3 clinical trial ZOSTER-049. The trial tracked participants for about 11 years after receiving Shingrix. The final data showed that RZV was effective in protecting adults over 50 against shingles for more than ten years. Shingles is caused by reactivation of varicella-zoster virus (VZV), which is also the causative agent of chickenpox. Most adults already have this virus in their bodies, and can

Zhitong FinanceApr 18 09:00 ET

Express News | NYSE Order Imbalance 51171.0 Shares on Sell Side

Moomoo 24/7Apr 17 15:50 ET

Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)

TipRanksApr 17 10:40 ET

GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years

Wednesday, GSK plc (NYSE:GSK) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants for up to approximately 11 years following initial vaccination with Shing

BenzingaApr 17 08:06 ET

GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea

Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatmentEAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-cla

BenzingaApr 17 05:32 ET

Express News | GSK Says New Long-Term Data Show Shingrix Continues To Provide Protection Against Shingles In Adults Aged 50 And Over For More Than A Decade

Moomoo 24/7Apr 17 05:30 ET